Neurocrine Biosciences, Inc. announced new research that helps define clinically meaningful improvement in overall health reported by people living with tardive dyskinesia who were treated with ...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new research that helps define clinically meaningful improvement in overall health reported by people living with tardive dyskinesia who ...
Neurocrine Biosciences (NBIX-0.41%) generated $959 million in revenue in Q2 2026, representing an increase of 39% year over ...
On October 7, 2026, Cerevance announced the top-line results of the Phase 3 ARISE trial for the investigational Parkinson's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results